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Abstract 
 
The medicinal properties of Manuka honey have been extensively studied, particularly in 
terms of its wound healing and antimicrobial activities. We have previously demonstrated 
that Manuka honey also has anti-cancer properties against a variety of cancer cell types in 
vitro as well as in preclinical cancer models. The cellular targets of the anti-cancer activity of 
Manuka honey, however, remain unknown. For the present study, we selected the triple-
negative human breast cancer cell line, MDA-MB-231, to investigate susceptibility to 
Manuka honey and to identify the potential signaling pathways affected. MDA-MB-231 
cancer cells are known to constitutively express activated STAT3 transcription factor. This is 
due to mutations in upstream tyrosine kinases that effectively maintain STAT3 in a 
phosphorylated, and thus activated, form. These cells are also known to secret IL-6 
constitutively, thus creating a positive feedback loop that drives their proliferation and 
survival. Our findings demonstrate that treatment with Manuka honey led to inhibition of 
STAT3 tyrosine phosphorylation in a concentration and time-dependent manner. Inhibition 
of STAT3 activity was observed as early as 15 minutes after cell co-culture with as little as 
1% solution of Manuka honey. Importantly, treatment with Manuka honey also led to 
decreased IL-6 production. As a consequence, we observed a reduction in the level of anti-
apoptotic protein Bcl-2 and an increased in the protein expression of cytochrome c, 
ultimately leading to the death of cancer cells. Heat-treatment of Manuka honey abolished its 
effect on STAT3 phosphorylation and cytocidal capacity. In conclusion, our findings identify 
novel targets affected by treatment with Manuka honey in triple negative human breast 
cancer cells. The influence of the blockade of this pathway by Manuka honey on other types 
of human cancers remains to be investigated. 
 
Keywords: Manuka honey, cancer, STAT3, IL-6, Triple negative breast cancer. 
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 )cibarA ni( tcartsbA dna eltiT
 
 لاھداف الجزیئیة لعسل المانوكا في سرطان الثدي البشري ا
  الملخص
عسل المانوكا لھ خصائص طبیة كثیرة منھا المساعدة على التئام الجروح و كمضاد 
حیوي و قد اثبتنا في دراسة سابقة أن لھ قدرة على قتل الخلایا السرطانیة. الھدف من الدراسة 
ا على الإشارات الخلویة في خلایا ثدي سرطانیة تعرف الحالیة ھو تحدید تأثیر عسل المانوك
متوفر في حالة نشطة نتیجة  3TATS. ھذه الخلایا تعرف بأن  132-BM-ADMباسم 
مفسفر )أي نشط(، بالإضافة إلى أن ھذه  3TATSطفرات في التایروزین كایناز الذي یبقي 
الدراسة أثبتت أن عسل المانوكا  الذي یحفز عملیات التكاثر و البقاء. نتائج 6-LIالخلایا تفرز 
( و ھذا %1دقیقة و باستخدام تركیز منخض من العسل ) 51في خلال  3TATSیثبط فسفرة 
التأثیر یتزاید بزیادة وقت التعرض و التركیز المستخدم. بلإضافة إلى ذلك عسل المانوكا قام 
البروتینات  . نتیجة لھذه التغییرات لاحظنا ھبوطا في مستوى بعض6-LIبخفض مستوى 
 ( و زیادة في السیتوكروم سي2-lcBالمسؤولة عن منع موت الخلایا المبرمج )
( مؤدیة إلى تحفیر موت الخلایا السرطانیة. لوحظ أن ھذه القدرات تفقد c-emorhcotyc)
عندما یتعرض العسل للحرارة العالیة. في الختام، ھذه الدراسة بینت أھدافا خلویة مھمة  لعسل 
في خلایا سرطان الثدي و مزید من الأبحاث مطلوبة لتحدید تأثیر عسل المانوكا على المانوكا 
 خلایا سرطنیة أخرى.       
 .موت الخلایا، سرطان الثدي ، نلسرطا، اعسل المانوكا: مفاھیم البحث الرئیسیة
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Chapter 1: Introduction 
	
1.1 Cancer: background 
Cancer is defined as multistep process that starts with a genetic mutation 
interfering with cellular signaling circuitry, causing the cell to acquire traits that 
sustain cellular immortality, enabling survival signals, chronic proliferation and 
ultimately leading to invasion and metastasis (Figure 1) [1]. This leads to the 
modification of the tumor microenvironment that favors tumor growth and self-
sufficiency. The dysregulation of the endogenous genes results in the activation of 
many silenced genes, manipulation of the molecular regulatory mechanisms, 
overexpression of growth signals and biased imbalance between pro-apoptotic and 
anti-apoptotic proteins [1].  
	
	
	
	
	
	
	
	
	
	
	
Figure 1: Acquired functional capabilities of cancer cells. Accessed on 30 
October 2015, from http://myelomacinderella.net/2015/03/cancer-hallmarks-
signalling-pathways-mm-drugs/cancer-functional-pathways-lg/.  
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Cancer is known to behave like “unhealed wound” characterized by heavily 
infiltrated immune cells creating inflammatory environment surrounding the tumor 
niche.  This provides molecules, such as growth and survival factors, and 
extracellular-matrix modifying enzymes that foster tumor progression, invasion, 
metastasis and angiogenesis [1]. Collectively, therefore, the tumor microenvironment 
plays a critical role in supporting the survival and growth of malignant cells.  
The tissue microenvironment is an important player that shifts the homeostasis 
balance, creating a favorable niche for a precancerous cell to become malignant. The 
transition from a normal cell to a malignant one involves two processes: initiation 
(one or more genetic mutations) and tumor promotion [2]. Numerous elegant studies 
have been published in support of this concept. In an early study carried out by 
David Dolberg and Mina Bissell, Rouse sarcoma virus (RSV), a virus that causes 
sarcoma in chickens, was injected into the wings of early embryos [3]. They found 
that these embryos grew normally even in the existence of an active src oncogene, a 
proto-oncogene that encodes a non-receptor tyrosine kinase protein [3]. What is more 
interesting is that when they removed the wings and the cells cultured for 24 hours, 
these cells that were infected with src oncogene become, transformed [3]. This 
clearly supports the notion that, the embryonic unique microenvironment inhibited 
the ability of vigorous oncogene such as src to cause sarcoma. Therefore, the tissue 
environment has an influential effect on malignant cells.  Even in the presence of 
malignant cells, the microenvironment is able to constrain tumor growth hence, any 
alteration can change the inhibitor into a promoter of tumor growth.  
The immune system has also been shown to play an important role in cancer 
progression. Based on autopsy studies, individuals who died from trauma were often 
found to have microscopic clusters of cancer cells, known as “in situ” carcinoma [4]. 
3	
	
	
	
	
In a 1934 study conducted on autopsies, of 292 male aged 50 years or more, who 
died from cancer-unrelated causes, 41 cases were found to harbor prostate carcinoma 
lesions, some a few millimeters in size, in their prostate gland [5].  Therefore, it is 
not unusual to develop cancerous lesions that may or may not advance to clinically 
diagnosed cancer. This is due to the immunosurveillance mechanisms that keep the 
growth of cancer cells under control [6]. Hence, successful growth of cancers occurs 
at the expense of a compromised immune system.  
Collectively, therefore, genetic instability, host’s immune system and tumor 
microenvironment play crucial roles in cancer initiation and progression. Our 
enhanced understanding of these factors will aid in the development of effective 
therapeutic anticancer strategies.   
1.2 Current Conventional Cancer Treatment  
Over the past 50 years, cancer therapeutic strategies have focused on three 
main treatment modalities: surgery, radiation and cytotoxic drugs. More recently, 
targeted based therapy and immunotherapy have become increasingly used as 
treatment options. These various modalities are used in combination to ensure the 
eradication of the cancerous tissue/cells [7].  
Surgery is one of the oldest approaches used against cancer. It is defined as a 
procedure used to remove or restore the diseased or injured portion of the body [8]. 
Surgery is useful as long as the tumor cells are confined and localized for easy 
removal. Therefore, it is considered as a possible curative method and doesn’t protect 
against cancer reoccurrence.  
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On the other hand, radiation is a therapy that uses beam of X-rays to cause extensive 
DNA damage in the tumor cells through the generation of free radicals, this damage 
can’t be repaired and thus leads to cell death [9]. Since the efficacy of radiotherapy 
depends on the generation of free radical species from oxygen, the hypoxic 
conditions within the tumor tissue act to limit the effectiveness of radiation [10]. 
Maintaining the tumor’s inner tissue in a hypoxic state allows the cancer cells to 
resist killing by radiotherapy. Even though this therapy is considered localized, both 
short and long-term complications are associated with radiotherapy. In the short-
term, cytotoxicity on highly proliferating cells, such as skin, hair, bone marrow and 
gastrointestinal track, causing vomiting, nausea, diarrhea, and severe 
immunosuppression [10]. Moreover, long-term effects of radiation include increased 
potential for the development of secondary cancer, infertility, joint problems and 
lymphedema [10]. 
Conventional chemotherapeutic agents target cancer cells and trigger their death 
through interfering with essential cellular processes [9]. Although rapid proliferation 
is a hallmark of cancer, the body also contains normal cells that tend to divide 
rapidly. For example cells of the bone marrow, oral cavity and mucosal lining of 
intestine, hair follicles, ova and sperms. Cancer complexity is as Walt Kelly, an 
American animator, quotes “We have met the enemy, and he is us”; cancer cell is 
much like a normal cell, but with abnormal properties [11]. Unfortunately, current 
chemotherapy regimens don’t distinguish between normal and cancerous cells, hence 
their systemic effect. Notwithstanding their toxicity, chemotherapeutic drugs have 
had an enormous impact judging by the improved overall survival rates observed in 
cancer patients, especially in Hodgkin's disease, acute lymphocytic leukemia of 
childhood, choriocarcinoma and Burkitt's lymphoma [12]. The lack of specificity 
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remains a serious concern and creates a major challenge for limiting the harmful 
effects on normal cells. The consequences of chemotherapy are sufficiently serious 
for many to express the need for “Treating the Treatment” [13]. These toxicities 
often occur at the level of the therapeutic dose and thus are unavoidable [13].  In 
addition, the combination treatment regimens are also a main cause of 
chemotherapy-associated toxicities. Because of the similarities in the side effects 
caused by many chemotherapy drugs, combination drug regimens often lead to 
additive toxicities, such as nephrotoxicity, cardiomyopathy, pulmonary damage and 
sterility [12, [14]. Psychiatric consequences, including depression, have been 
reported among breast cancer survivors as a complication of chemotherapy [15]. 
Given that some chemotherapeutic drugs are carcinogenic in nature, particularly 
alkylating agents such as cisplatin, the development of secondary malignances 
remains a serious long-term side effect [16, 17] . Because chemotherapeutic drugs 
often target cancer cells, they do not actively utilize the patient’s immune system in 
their eradication. One of the well-recognized consequences of chemotherapy is bone 
marrow suppression, which results in neutropenia and lymphopenia among other 
effects. In this way, chemotherapeutic drugs can be thought of as acting against the 
body’s anti-tumor immune defense systems, thereby contributing to another layer of 
potentially deleterious complication. The failure to harness the immune system in the 
fight against cancer cells along with chemotherapy is a major hurdle with the 
currently used therapeutics toward a complete cure without recurrences. The ideal 
cancer treatment should not only focus on killing cancer cells but, rather, it should 
employ the body’s defense mechanisms to achieve a durable disease-free survival 
[18]. It is generally believed that tumor cells arise spontaneously and continuously 
throughout one’s life span. For the major part, a healthy immune system can 
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recognize and eliminate, or at least control, these mutated cells effectively [19]. 
Development of symptomatic cancer is inherently linked to either a failure in the 
immune surveillance system or to the ability of cancer cells to develop mechanisms 
that effectively help in evading anti-tumor immune responses. The recent astounding 
successes reported in clinical trials using newly developed immunotherapeutic drugs 
are a testament to the critical role of the immune system in fighting cancer [20-22]. 
Finally, to overcome current conventional treatment obstacles, a multidimensional 
treatment strategy that addresses the whole body is needed, one that efficiently 
destroys cancer cells while maintaining the patient’s strength and vitality.  
1.3 Natural Therapies in Cancer Treatments 
Despite the remarkable breakthroughs in cancer research, tumor resistance, 
recurrence and toxicities associated with current standard therapies are considered 
major challenges facing cancer treatment. This may explains the overall modest 
improvement in cancer death rate since 1950 [23]. Over the past 75 years, cancer was 
the second leading cause of death in the USA [24]. Worldwide, about 14.1 million 
new cases and about 8.2 million death occurred in 2012 [25]. This clearly indicates 
the failure of the current conventional treatments to eradicate cancer.  
Given the above facts, screening for new anti-cancer agents with novel properties 
becomes a real necessity. Ideally, anti-tumor compounds that have the capacity to 
limit cancer resistance, reduce drug-associated toxicities, or enhance the safety 
profile and efficacy of current chemotherapeutic drugs are required. Recognizing that 
Nature is the perfect reservoir for drug discovery, the National Cancer Institute (NCI) 
announced a large-scale screening of natural compounds that possess anticancer 
activity in 1960 [26]. Natural compounds can be found in marine life forms, 
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microorganisms, plants or in dietary agents [27]. Key factors underlying the potency 
of natural products include chemical diversity, structural resemblance of protein 
targets throughout many species [28, 29]. The bioactive compounds are usually 
tested either as crude form or as pre-fractionated extracts [28]. Remarkably, many of 
these novel compounds were reported to exhibit various biological effects, for 
example antimicrobial or anti-proliferative activities, on different types of cancer 
[30]. Nature has been an inspiring and continuous source for many novel drug 
discoveries but many more compounds a wait to be discovered.  
1.4 Honey: An ancient therapy 
One of nature’s potent drugs is honey, a natural substance formed from the 
nectar and the secretion of plants by the honeybees, Apis mellifera [31]. After the 
intake of the nectar, the bees add a particular enzyme made in their body that 
converts the nectar into honey [32]. Different types of honey are made depending on 
the nectar source (plants).  Honey was known as a traditional medicine for as far 
back as 4000 years ago [33]. The ancient Egyptians, Chinese, Greeks and the 
Romans described the use of honey in wound healing and in the treatment of gut 
diseases [34]. Hipprocrates recommended the intake of honey to preserve health and 
physical strength [35]. Also, the Nobel Quran, religious text of Islam, emphasizes the 
potential benefits of honey and bees thus “And your Lord inspired to the bee, Take 
for yourself among the mountains, houses, and among the trees and [in] that which 
they construct. Then eat from all the fruits and follow the ways of your Lord laid 
down [for you]. There emerges from their bellies a drink, varying in colors, in which 
there is healing for people, indeed in that is a sign for a people who give thought” 
(Surat Al-Nahl “The Bees”, Aya 69).  
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Nowadays, modern science proves and confirms what has been known several 
thousands of years ago, the medicinal properties of honey. The therapeutic potential 
of honey is attributed mainly to its wound healing properties. However, current 
evidence indicates that honey has a broad spectrum of actions.  In fact, it contains 
compounds that act as antioxidant, anti-inflammatory, antibacterial and anticancer.  
Honey medicinal properties and cancer pathological behavior revealed an inverse 
relationship that Dr. Nor explained in her review [36], summarized in Figure 2.  
 
 
Evidence-Based Complementary and Alternative Medicine 5
Properties of honey Causes of cancer
Is a scavenging agent for toxic free radicals
Is natural antimicrobials
Has high antioxidant
Is natural immune booster
Is natural anti-inflammatory agent
Is “fixer” for chronic ulcers and wounds
Has potential as cancer therapeutic agent
Cause unknown
Genetic inheritance
Chronic nonhealing ulcers, e.g., squamous cell
carcinoma developing in chronic traumatic
wounds
Chronic inflammation, e.g., colorectal carcinoma in
Crohn’s disease and ulcerative colitis
chronic illness, obesity
Low immune status, e.g., due to diabetes,
virus (HPV, EBV, Hep. B, C), parasites
(schistosomiasis), fungus (Aspergillus flavus)
Accumulation of toxic free radicals reactive
oxygen species due to
• Smoking• Alcohol
• Obesity
• Chronic infections, etc.
C
an
ce
r
H
on
ey
Chronic infections, e.g., bacteria (H. pylori),
Figure 4: The inverse relationship of honey and cancer.
response, the body defense mechanisms in trying to rid
of the irritants. In general inflammatory responses are
beneficial and protective to us, but at times, inflammatory
responses are detrimental to health. Honey is a potent anti-
inflammatory agent. Infants suffering from diaper dermatitis
improved significantly after topical application of a mixture
containing honey, olive oil, and beeswax after 7 days [68].
Honey provides significant symptom relief of cough in
children with an upper respiratory tract infection (URTI)
[69]. It has been shown to be effective in management
of dermatitis and Psoriasis vulgaris [70]. Eight out of 10
patients with dermatitis and five of eight patients with
psoriasis showed significant improvement after 2 weeks on
honey-based ointment [70]. Honey at dilutions of up to
1 : 8 reduced bacterial adherence from 25.6 ± 6.5 (control)
to 6.7 ± 3.3 bacteria per epithelial cell (P < 0.001) in
vitro [71]. Volunteers who chewed “honey leather” showed
that there were statistically highly significant reductions in
mean plaque scores (0.99 reduced to 0.65; P = 0.001)
in the manuka honey group compared to the control
group suggesting a potential therapeutic role for honey for
gingivitis, periodontal disease [72], mouth ulcers, and other
problems of oral health [73].
A case report of a patient who had chronic dystrophic
epidermolysis bullosa (EB) for 20 years healed with honey
impregnated dressing in 15 weeks [74] after conventional
dressings and creams failed. This illustrates the usefulness of
honey as an anti-inflammatory agent. Chronic inflammatory
process has risk of cancer development.
6. Honey As Natural Antimicrobials
Everyday we are exposed to all kinds of microbial insults
from bacteria, viruses, parasites, and fungi. Honey is a
potent natural antimicrobial. The most common infections
humans get are from staphylococcal infection. Antibacterial
effect of honey is extensively studied. The bactericidal
mechanism is through disturbance in cell divisionmachinery
[75]. The minimum inhibitory concentration (MIC) for
Staphylococcus aureus by A. mellifera honey ranged from
126.23 to 185.70mgml−1 [76]. Honey is also effective against
coagulase-negative staphylococci [77]. Local application of
raw honey on infected wounds reduced signs of acute
inflammation [78], thus alleviating symptoms. Antimicro-
bial activity of honey is stronger in acidic media than in
neutral or alkaline media [78]. The potency of honey is
comparable to some local antibiotics. Honey application
into infective conjunctivitis reduced redness, swelling, pus
discharge, and time for eradication of bacterial infections
[78]. When honey is used together with antibiotics, gen-
tamycin, it enhances anti-Staphylococcus aureus activity, by
22% [79].When honey is added to bacterial culture medium,
the appearance of microbial growth on the culture plates is
delayed [80]. Mycobacteria did not grow in culture media
containing 10% and 20% honey while it grew in culture
media containing 5%, 2.5%, and 1% honey, suggesting that
honey could be an ideal antimycobacterial agent [81] at
certain concentrations.
Figure 2: The inverse relationship of honey and the cancer. Obtained from: Nor Hayati 
Othman, Honey and Cancer: Sustainable Inverse Relationship Particularly for 
Developing Nations—A Review, Evidence-Based Complementary and Alternative 
Medicine, vol. 2012, 10 pages, 2012. 
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Honey, as Dr.Nor described, can be called as “Natural cancer vaccine”, due to its 
several bioactivities. It reduces the chronic inflammation, a pathological risk of 
cancer development [36]. It also boosts the immune system, since cancer is caused 
due to failure in the immunosurveillance system [36].  
According to Fukuda et.al [37], Jungle honey (JH), a honey from the forest area in 
Nigeria, contains chemotactic activity for neutrophils. More importantly, when mice 
with Lewis lung carcinoma/2 (LL/2) treated i.p with JH (1 mg/mouse/day). It was 
found that frequency and mean weight of LL/2 tumors were reduced [37]. Histology 
revealed a massive neutrophil infiltration in the tumor tissue, hence they suggested 
that the reduce tumor burden was due to the neutrophils inhibiting the tumor growth 
[37].  
Furthermore, it has been shown by many researchers [36, 38, 39] that honeys from 
different geographical and climatic zones and floral sources, can induce apoptosis in 
various cancer cells types. Honey is effective in killing cancer cells, because it 
contains several kinds of phytochemicals (phenolic and flavonoid compounds), 
which explains its high anti-inflammatory and antioxidant activity [36].  Yaacob and 
colleagues investigated the anticancer effect of Tualang honey, wild rainforest honey 
from Malaysia. They found that this honey exhibit cytotoxic potential against human 
breast adenocarcinoma (MCF-7 and MDA-MB-231) and in human cervical 
carcinoma (Hela) [40]. They observed a depolarization of the mitochondrial 
membrane potential that leads to the induction of apoptosis, an ideal way of death 
[40]. Jubri et al. demonstrated the anti-proliferative activity of Gelam honey, a 
monofloral honey from Malaysia, against human liver carcinoma cells (HepG2), 
which is due to the induction of apoptosis [41]. On the other hand, it did not have an 
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affect on normal liver cells viability (WRL-68), which indicates a selective 
cytotoxicity against liver cancer cells [41]. 
Notably, the honey is considered as chemopreventive agent, nature substances that 
reverse, suppress, or prevent the development of cancer [42]. A study done by 
Oršolić et al. revealed the pronounced anti-metastatic properties of the honey, when 
mice received honey orally (2g/kg/day) for 10 consecutive days before tumor cell 
inoculation in the lung [43]. Interestingly, Mabrouk and colleagues showed the 
protective effect of honey and Nigella grains against provoked carcinogenesis by 
methylnitrosourea (MNU), a chemical that is classified as human carcinogen, in 
Sprague Dawely rats [44]. This protection reached 100% of rats and there was no 
evidence of an increase in the malondialdehyde (MDA) nor the nitric oxide (NO) in 
the sera of these animals, both indicators of MNU-induced oxidative stress [44].  
Honey is a potent antioxidant and scavenger of toxic free radicals, thus preventing 
DNA damage to the cells [36, 38, 39].  Blasa et al. investigated the effect of Italian 
honey flavonoid as antioxidant agent; they showed that honey flavonoid prevents 
oxidative damage against human red blood cells [45].  
In addition to the above mentioned honey properties, the honey contains numerous 
kinds of phytochemicals that varied in concentration and availability. Recently, many 
researchers become interested in studying the anticancer activities of 
phytochemicals. Phytochemicals are chemicals compounds created by the plants and 
present in the honey that gives a distinctive flavor, smell, and color. Polyphenols can 
be narrowed down to flavonoids and phenolic acids. Extensive research has shown 
the therapeutic properties of those polyphenols. For example, caffeic acid pheneyl 
ester (CAPE), a natural phenolic compound found in honey and propolis extract, was 
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shown by Maruta et.al [46] to inhibit vital signaling pathways in cancer growth, 
proliferation and survival. It was found that CAPE blocked completely the growth of 
the human cancer Neurofibromatosis (NF1), a type of cancer that is found in the 
protective lining of the nerves that extend from the spinal cord into the body [47]. 
Moreover, CAPE was found to inhibit specifically nuclear factor-kappa-B (NFκΒ), a 
transcription factor that can induce the expression of multiple target genes important 
for cell proliferation, survival, metastasis and angiogenesis [30].  
Krol et.al investigated the cytotoxic effect of propolis extract (EEP) and thirteen 
other phenolic compounds on the human cervical cancer cell line, HeLA [48]. When 
EEP was added together with TRAIL (tumor necrosis related apoptosis inducing 
ligand), a protein that binds to the death receptor and programmed cell death, it was 
found that HeLA cells, a TRAIL-resistant cell line, was significantly sensitized to 
TRAIL mediated apoptosis [48]. This clearly indicated the EEP could work 
synergistically in combination TRAIL and overcomes cancer cell resistant to 
extrinsic programmed cell death. These scientific findings seem to prove the 
efficiency of different honey types against several forms of cancer, both in cell 
cultures and animal models. The honey properties strongly support the therapeutic 
potential use of honey in cancer therapy. A further in-depth investigation is needed to 
uncover underlying mechanism/s of honey as a cancer treatment. In summary, cancer 
should be attacked at different levels rather than one specific angle; thus might 
reduced the chance of the cancer become resistant to the current treatment and 
recurrences. 
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1.5 Manuka Honey  
Manuka honey is a monoforal honey in which the bee depends primarily on 
one plant to collect the nectar from and hence it is named after this plant [49]. This 
honey originates from the Manuka tree, flowering plant called Leptospermum 
scoparium, which flourishes as a shrub or a small tree throughout New Zealand and 
Eastern Australia (Figure 3) [49]. The native people recognize the Manuka tree as an 
“Antibacterial Medicine”. 
 
 
 
 
 
 
 
 
The chemical composition of the Manuka honey consists of:  sugar mainly fructose 
and glucose about 95%; enzymes such as invertase (breakdown sucrose), glucose 
oxidase (oxidizes glucose and converts oxygen into hydrogen peroxide) and catalase 
(catalyzes the hydrogen peroxide into water and oxygen); amino acids; vitamins; 
minerals; flavonoids and phenolic acids [39]. Table 1, below, illustrates in details 
about the flavonoids, phenolic acids and other compound found in Manuka honey.  
Figure 3: Manuka tree, Leptospermum scoparium. Accessed on 11 
October 2015, from http://www.soulsister.co.za/wp/2013/08/manuka/. 
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Table 1: Most common flavonoids, phenolic acids and other compound in Manuka 
honey [49] 
 
Flavonoids and 
Phenolic Acids 
Reference  Other compounds Reference  
Caffeic Acid  [50] Phenyllactic acid   
 
[39] 
Isoferulic Acid  [39] 4-Methoxyphenolactic 
Acid  
 
[39] 
p-Coumaric Acid [50] Kojic Acid   
Gallic Acid  [51] 5-Hydroxymethyfurfural  [52] 
4-Hydrobenzonic 
Acid  
[39] 2-Methoxybenzoic Acid  
 
[39] 
Syringin Acid  [51] Phenylacetic Acid  [39] 
Quercetin [50] Methyl syringate  [39] 
Leuteolin [50] Dehydrovomifoliol [39] 
8-Methoxykaempferol  [50] Leptosin  [39] 
Pincocembrin  [50] Gyoxal [39] 
Isorhamnetin  [50] Methylglyoxal  [52] 
kaempferol [50] 3-Deoxyglucosulose  [39] 
Chrysin [50] - - 
Galangin [50] - - 
Pinobanksin  [50] - - 
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Manuka honey has been extensively studied due to its various pharmacological 
activities in wound healing, fungal/bacterial infections, ophthalmic conditions,, 
gastrointestinal diseases and skin ulcers [53]. Dr. Peter Molan discovered the first 
notable feature of the Manuka honey: wound healing and antibacterial properties. 
Manuka honey pH ranges between 3.2 to 4.5, thus prevents the growth of microbes, 
since they like to live at pH 7.2 -7.4 [54]. Additionally, honey osmolality, due to the 
high sugar content, draws fluids out of the tissue and leaves the wound area in a 
moist environment accelerating the healing processes [54, 55].  
Surprisingly, Manuka honey antibacterial potency is extraordinary, because it is the 
only honey that can kill bacteria in non-peroxide fashion. Dr.Molan proved this fact 
by adding catalase to the honey and measuring bacterial zone of inhibition. The 
result was that even in the presence of catalase the Manuka antibacterial activity was 
stable [56]. This experiment clearly indicated the presence of other compounds that 
act as anti-bactericidal.  
Honey is well known as natural immune stimulator. It was reported that Manuka 
Honey was able to induce primary human monocytes cells to produce inflammatory 
cytokine [57]. Interestingly, they also investigated which components that are present 
in Manuka honey are responsible for this induction. They found a heat sensitive 5.8 
kDa component different than a Lipopolysaccharide (LPS), since it is heat stable, 
was able to immunemodulate and stimulate monocytes, immune cells that circulate 
in the blood, to produce inflammatory cytokines via this Toll-like receptor 4 (TLR4) 
[57]. Moreover, a study done in rats by Medhi and colleagues, found that oral 
administration of Manuka honey (5g/Kg and 10g/Kg) was able to reduced the 
colonic inflammation in the experimentally induced inflammatory bowl disease 
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compared to untreated rats [58]. The authors explained this protection through lipid 
restoration and antioxidant parameters improvement [58].  
1.6 Triple Negative Breast Cancer (TNBC) 
Breast cancer is the second most common type of cancer diagnosed in woman 
and considered as major cause of death in woman [25]. According to the World 
Cancer Research in 2012, around 1.7 million new cases of breast cancer worldwide 
were diagnosed [25]. In the clinic, breast cancer is classified molecularly into 
different subgroup depend on the expression of estrogen receptor (ER), progesterone 
receptor (PG) and the overexpression of human epidermal growth factor receptor 2 
(Her-2/Neu) [59]. On the other hand, tumors that do not express any of the above-
mentioned markers are called triple negative breast cancer (TNBC) [60]. In the latter 
subgroup, patients tend to have poor prognosis, can’t be treated with Her-2 targeted 
therapies nor hormonal therapy and have high recurrence rate [60]. Out of all breast 
cancer subtypes, 10-15% approximately accounts for TNBC [59]. They have 
mesenchymal-like features and express epidermal growth factor receptor [60]. 
TNBCs are considered aggressive and difficult to treat (depend on stage at time of 
diagnosis), they are frequently chemotherapy-resistant, with p53 mutation and more 
importantly have up-regulation of IL-6 and STAT3 [61]. Due to the lack of targeted 
therapy, understanding the molecular cell biology of the TNBC may aid to identify 
new targets for drug discovery.  
STAT3 is persistently activated by tyrosine phosphorylation in about 50% of the 
primary breast carcinoma [62]. Constitutive activated STAT3 is not only seen in 
breast cancer but also found in head and neck, melanoma, multiple myeloma, ovarian 
cancer, adult acute myeloid leukemia, lung cancer, prostate cancer and glioblastoma 
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[63-65]. In TNBC specifically, tyrosine phosphorylated STAT3 is constitutively 
activated in both tumor derived-cell lines and human specimens [61, 66]. Several 
studies showed that STAT3 activation resulted on TNBC progression; hence STAT3 
is a possible promising therapeutic target [62, 67, 68].  
1.7 Signal Transducer and Activator of Transcription 3 (STAT3) Signaling 
Pathway  
STAT3 is a latent cytoplasmic protein that functions as secondary messenger 
and as a transcription factor. It belongs to a family comprise of seven different Stat 
proteins: STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6 [69] . All 
STAT protein share the same structural features and mechanisms of activation [64].  
They usually consist of ~850 amino acids long for STAT2 and 6, and about 750 to 
795 amino acid long for STAT 1,2,3,4, 5a and 5b (Fig.4) [70]. The DNA binding 
region in the STAT molecules controls the specificity of binding and because this 
region is conserved among the STAT proteins, they bind to the same DNA sequence. 
Transcription activation domain (TAD) located in the C-terminal of the STAT 
proteins is required for the activation of target gene transcription.  
   
 
 
		
any more family members exist.
Phosphorylation on a single tyrosine lo-
cated around residue 700 in each protein is
obligatory for STAT activation (1, 2) (Fig.
1). Ligand-activated receptors that catalyze
this phosphorylation include receptors with
intrinsic tyrosine kinase activity [for exam-
ple, epidermal growth factor (EGF), platelet-
derived growth factor (PDGF), and colony-
stimulating factor–1] as well as receptors that
lack intrinsic tyrosine kinase activity but to
which Janus kinases (JAKs) are nonco-
valently associated (3, 6). The mammalian
JAKs include four large tyrosine kinases
(;1200 amino acids) characterized by a
COOH-located kinase and a neighboring
domain that resembles but is not an active
kinase. Receptors to which JAKs are bound
are often referred to as cytokine receptors.
Their ligands include IFN-a, -b, and -g;
interleukins (IL) 2 to 7, 10 to 13, and 15;
and erythropoietin, growth hormone, prolac-
tin, thrombopoietin, and other polypeptides.
Ligand-mediated dimerization of either
type of receptor is believed to result in recip-
rocal tyrosine phosphorylation, and conse-
quent activation, of the intrinsic or the at-
tached kinase (6). Phosphorylation of the
kinase is the first of three tyrosine phospho-
rylations culminating in STAT activation
(Fig. 2). The activated JAKs phosphorylate
tyrosine sites on the cytoplasmic tail of the
receptor that serve as docking sites for the
SH2 domains that occur in all the STATs.
The receptor-bound STAT is then phospho-
rylated on tyrosine. This chain of events was
first shown for the IFN-g receptor (7) and
has since been shown for a variety of other
receptors (2, 3, 6, 7).
The activated JAK protein kinases do
not seem to have specificity for a particu-
lar STAT substrate. For example, different
receptors can activate the same STAT
molecule through phosphorylation of the
same tyrosine site, even though they acti-
vate distinct JAKs (6, 8). Recombinant
receptor molecules with different JAK
binding sites but with the same STAT
docking sites activate the same STAT (8,
9). Also, STAT docking sites can be add-
ed to heterologous receptors, allowing
docking and STAT activation by the li-
gand specific to the extracellular domain
of the recombinant receptor (10). Finally,
exchange of SH2 domains between Stats 1
and 2 reversed the specificity of receptor
activation of the recombinant molecules
(11). Thus, the initial specificity for most
STAT activation appears to be deter-
mined by specific interactions between
STATs and receptors (Fig. 2A).
This relatively simple picture for most
STAT activations may understate the com-
plexity of STAT-receptor-kinase interac-
tions because in several cases more compli-
cated interactions occur (Fig. 2, B and C).
At least some STAT binding to receptors
that have not bound ligand has been report-
ed (12). This implies binding to receptor
sites other than phosphotyrosine residues.
The role of this binding in STAT activation
is not yet clear (3). At the IFN-a receptor
both Stat1 and Stat2 become activated, but
Stat1 requires the presence of a tyrosine-
phosphorylated Stat2 to become phospho-
rylated, whereas Stat2 can dock and be
phosphorylated on its own (13). The NH2-
terminal region of Stat2 as well as the phos-
photyrosine of Stat2 are required to activate
Stat1 (3, 12) (Fig. 2B). Stat5 can be phos-
phorylated at the IL-6 receptor apparently
without receptor tyrosine docking sites (14);
it appears to interact directly with a
domain of JAK2 (Fig. 2C). Further work on
STAT activation may well reveal other such
interactions.
Stats 1, 3, and 5 can be activated by
various receptor tyrosine kinases (RTKs),
but much less is known about the specificity
of RTK activation of STATs. The enzymatic
activity of the receptor is required (15), and
tyrosine residues outside the catalytic center
of the EGF receptor are known to be re-
quired for activation of Stats 1 and 3 (16,
17). Association of the STAT molecules
with these receptor phosphotyrosine residues
is implied but has not been directly demon-
strated. The activated EGF receptor kinase
can phosphorylate the activating sites on
STATs in vitro (18). The EGF receptor is
composed of members of a large protein fam-
ily (19). Differential activation of Stats 1, 3,
and 5 by EGF in various cell types might
reflect the use of different members of this
receptor family with different affinities for
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interaction domains in the STATs listed at the left. The NH2-terminal (leftmost) domain of Stats 1 and 4 is
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in that molecule.
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Figure 4: Structural properties of STAT proteins. Obtained from: James E. 
Darnell, STATs and Gene Regulation, Science 277, 1630 (1997). 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The activation of STAT proteins under normal condition is dependent on cytokine 
(such as IFN-α, -β, -γ, IL-2, IL-6 and IL-7) or growth factor (such as EGFR, HER2 
and PDGFR) stimulation that binds to the receptor tyrosine kinase (RTK) or cytokine 
receptors [70]. Also STAT proteins can be activated through non-receptor tyrosine 
kinase such as v-Src or ABL [70].  
Following ligand-mediated receptor dimerization, the tyrosine kinase-associated with 
the receptor, for example Janus kinase (JAK) or Src, phosphorylates the tyrosine 
residue in the cytoplasmic tails of the adjacent receptor molecule 
(transphosphorylation).  Thus creates docking site for the recruitment of STAT 
molecule (monomeric, non-phosphorylated) via SH2 domain. As a result, STAT 
protein becomes tyrosine phosphorylated by the JAK. Phosphorylated STAT 
dimerize with other phosphorylated STAT through an interaction between 
phosphorylated tyrosine residue in the SH2 domain of each STAT molecule.  
Consequently, STAT-STAT dimer translocate to the nucleus, where they bind and 
activate transcription of targets genes (figure 5) [69].       
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Figure 5: STAT signaling pathway. Obtained from: Buettner et al., Activated 
STAT Signaling in Human Tumors Provides Novel Molecular Targets for 
Therapeutic Intervention. Clinical Cancer Research, 2002, Vol. 8, #4: 945-954.  
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Chapter 2: Summary and Rational 
	
Hypothesis  
Given the central role of IL-6/STAT3 signaling pathway in proliferation and survival 
of MDA-MB-231 and other human triple negative breast cancers. We hypothesize 
that treatment with Manuka honey could block component to this pathway leading to 
growth arrest.    
Rational  
• Aberrant STAT3 activity is important in cancer development and progression  
• High IL-6 expression and constitutive STAT3 activity have been correlated to 
poor prognosis in-patient with advanced breast cancer and resistance to 
current chemotherapy treatment.    
• Genes regulated by STAT3 play major role in malignancy through 
dysregulation of many important cell-signaling pathways that favor cancer 
proliferation, survival, angiogenesis, immune modulation and metastasis.     
 
Objective  
The overall objective of this study is to identify proximal targets of the Manuka 
honey treatment of cancer cells and to investigate the potential role of Manuka honey 
in modulating IL-6/IL-6 receptor/JAK2/STAT3 signaling pathway.   
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Chapter 3: Material and Methods 
	
3.1 Summary of materials used suppliers 
2.2 Western blot Standard solution 
1M Tris-CL (pH=7.6): 15.76g Tris-base into 100ml deionized water (dH2O), and 
adjust the pH with HCL to “7.6”. 
6x sample Buffer (10 ml): 0.375M Tris pH 6.8, 12% SDS, 60% glycerol, 0.6M DTT, 
0.06% bromophenol blue. 
10x Running Buffer (For 1 Liter): 30g of Tris-base, 140g Glycine, 10g SDS, dissolve 
in 1L-dH2O.  
10x Transfer Buffer (For 1 Liter): 30g Tris-base, 144g Glycine, dissolve in 1L-dH2O. 
10x TBS Buffer (For 1 Liter): 24.2g Tris-base, 80g Nacl, dissolve in 1L-deionized 
water (dH2O) and adjust the pH with HCL to “7.6”.  
1x T-TBS buffer for 1 liter (membrane washing buffer): 100ml of 10x TBS buffer 
with 900ml of dH2O per a liter, then add 0.1% Tween.  
Materials Company 
BSA Sigma 
10 mm tissue culture treated culture dishes  Corning, NY,USA  
96 well tissue culture plates  Corning  
6 well tissue culture plates  Corning 
NaCl Sigma 
Tris-base  Sigma  
Glycine Sigma 
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 1.5M Tris-CL buffer for resolving gel (pH 8.8): 18.15g of Tris-base into 70ml 
dH2O, adjust the pH with HCL to “8.8” and then make up volume to 100ml. 
10% Ammonium persulfate (APS): 1g Ammonium persulfate in 10ml dH2O, store at 
-30˚C in 1ml aliquots.  
 
3.3 Antibodies  
Antibody Catalog # Company Concentration/dilution 
used 
Anti-STAT3 
Tyr705 
9131 Cell Signaling 
Technology  
1:1000 
Anti-STAT3 4904 Cell Signaling 
Technology 
1:1000 
Anti-β actin 4967 Cell Signaling 
Technology 
1:1000 
Anti-IL-6 12153 Cell Signaling 
Technology 
1:1000 
Anti-Bcl2 sc-7382 Santa cruz 
Biotechnology 
1:1000 
Anti-cytochrome c sc-13561 Santa cruz 
Biotechnology 
1:500 
Anti-cMyc P68  e-Bioscience  1:1000 
Anti-NFκB P65 8242 Cell Signaling 
Technology 
1:1000 
Anti-pNFκB P65 3033 Cell Signaling 
Technology 
1:1000 
Anti-SOCS3 2923 Cell Signaling 
Technology 
1:1000 
Anti-phospho-
Tyrosine  
(P-Tyr-1000) 
8954 Cell Signaling 
Technology 
1:1000 
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3.4 Cell lines  
The triple negative human breast cancer cell line, MDA-MB-231, was 
obtained from Prof.Samir Attuib, department of Pharmacology and Therapeutics, 
Collage of Medicine and Health Sciences [71]. Tumor cells were maintained in a 
complete Dulbecco's modified Eagle's medium (DMEM) containing 5% Fetal 
Bovine Serum (FBS) and antibiotics (Penicillin 100U/mL; for Streptomycin 
100µg/mL) at 37°C (all reagents from HyClone, GE healthcare Life Sciences, Utah, 
USA) [72].  
3.5 Western Blot Analysis  
MDA-MB-231 cells (4x106 cells/well) were seeded in 100mm x 20mm 
culture dish for overnight in 2% FBS DMEM growth medium. The next day 1% and 
5% Manuka honey was diluted in 5% DMEM medium and added after the removal 
of the previous media. The incubation time of the Manuka treatment started from 
0.25, 0.75, 0.5, 1,4,6 and 12 hours. At the end of the incubation period, cells were 
harvested, washed and lysed using RIPA buffer (25mM Tris-CL (pH=7.6), 150 mM 
sodium chloride (NaCl), 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium 
dodecyl sulfate (SDS), inhibitor cocktail (50mM PMSF, 1M sodium floride, 1M 
protease inhibitor and 1M sodium orthovandate). The whole cell lysates were kept on 
ice for 30 minutes and vigorously vortex mixed every 15 minutes before 
centrifugation at 10,000 rpm for 20 minutes at 4°C to remove insoluble material.  
Protein concentration in the samples was determined using Bradford protein assay 
(Bio-Rad, California, USA). Afterwards 60-80 µg of total proteins were boiled in 6x 
loading buffer (0.375M Tris pH 6.8, 12% SDS, 60% glycerol, 0.6M DTT, 0.06% 
bromophenol blue) for 5 minutes. Then separated by SDS polyacrylamide gel (SDA-
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PAGE) and transferred to a nitrocellulose membrane. The membrane was blocked 
with 5% non-fat milk for 1 hour and probed with appropriate primary antibodies 
overnight at 4°C. The blot was washed 3 times for 5 minutes, and then exposed to 
horseradish peroxidase-conjugated secondary antibodies (1:2000, Cell Signaling, 
MA, USA) for 1 hour. Protein bands were visualized using the ECL Plus western 
Blotting Substrate System (Pierce, Thermo Fisher scientific, MA, USA). The 
chemiluminescent band signal was detected by Typhoon FLA 9500 imaging machine 
(GE Healthcare Life Sciences, UT, USA). The Densitometric analysis on blots was 
quantified using ImageJ (National Institutes of Health, USA).  
3.6 IL-6 cytokine western blotting Analysis  
MDA-MB-231 cells (4x106 cells/well) were seeded in 100mm x 20mm 
culture dish for overnight in 2% FBS DMEM growth medium. The next day 1% and 
5% Manuka honey was diluted in 5% DMEM medium and was added after the 
removal of the previous media. The total incubation time of the Manuka treatment 
was 4.5 hours. The cells were treated with Manuka honey for 0.5 and, then, Brefeldin 
A (BFA), fungal metabolite that inhibits protein trafficking from endoplasmic 
reticulum to Golgi apparatus (Catalogue# 9972, Cell Signaling Technology, MA, 
USA), was added at 1µg/ml concentration for further 4 hours, to trap enough IL-6 
cytokine intracellularly to be detect with western blotting. Afterwards protein 
extraction and western blot protocol was followed as described above.  
3.7 In vitro viability assay 
MDA-MB-231 cells were seeded into 96-well plate at 5x103 cells/well in 
supplemented 2% FBS DMEM culture medium. Serial dilutions of Manuka (5% and 
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1%) prepared in sterile culture medium were then added to each well.  All 
determinations were done in duplicate. After 12, 24 or 48 hr incubation at 37°C, cell 
viability was determined using CellTiter- GloH Luminescent cell viability assay 
(Promega, Madison, WI, USA). Luminescent signal was measured using GloMax 
Luminometer system (Promega, Madison, Wisconsin, USA). Data were presented as 
percent cell viability of experimental groups compared with that of the untreated 
cells, the viability of which was taken as 100%.  
3.8 Reverse Transcription Reaction 
RNA was reverse transcribed using TaqMan reverse transcription reagent 
(Applied Biosystems #N8080234). Each master mix reaction contained 10x RT 
buffer, 25mM MgCl2, deoxy NTPs mixture (2.5mM), random hexamers (50µM), 
RNAase inhibitor (20U/µl) and MultiScribe RT enzyme. The master mix was 
aliquoted into separate PCR tubes. RNA was added (1µg/10µl per reaction) and total 
volume was made up to 50µl with nuclease-free water. The one step RT-PCR 
reaction was run on GeneAmp PCR System 2700 from Applied Biosystems, under 
the following conditions: hexamer incubation for 10 minutes at 25°C, reverse 
transcription at 48°C for 30 minutes and reverse transcriptase inactivation at 95°C for 
5 minutes. Samples were held at 4°C for a maximum of 1 hour until they could be 
removed and stored at -20°C. 
3.9 Real time PCR reactions 
The real time PCR was performed using TaqMan gene expression assay as 
specified below and amplified using the 7500 Real Time PCR System (Applied 
Biosystems). Each 20µl PCR reaction contained 10µl of 2xTaqMan Universal 
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Master Mix (Applied Biosystems #4440047), 1µl of 20x TaqMan assay Mix 
(Applied Biosystems #4331182), 2µl cDNA and 7µl nuclease free water. A negative 
PCR reaction was also carried out using only the reaction mixture without cDNA in 
order to ensure that there was no DNA contamination .The thermal cycling 
conditions were as follows: 95°C for 10 minutes (inactivation of reverse transcriptase 
and activation of TaqMan polymerase), 95°C for 15 seconds (denaturation of 
dsDNA) and 60°C for 1 minute (annealing/extension- fluorescent data collected 
during this step) for a total of 40 cycles with the threshold set as 0.2. Data was 
analyzed using the Ct values for each sample that were in duplicates. Results were 
normalized to HPRT (Hypoxanthine-guanine phosphoribosyl transferase) and the 
mRNA fold change was determined using the following equation: 
Fold change= 2 [   Ct (treated)] / 2 [  Ct (control)], where    Ct(treated) = threshold cycle (Ct) 
for target gene after treatment - Ct for HPRT after treatment and   Ct(control) = Ct 
for target gene untreated - Ct for HPRT untreated. Control used was untreated cells.  
The assay ID of the primers used is as follows:  
PIAS3 (Hs00966035_m1), PTPN1 (Hs00942477_m1), HPRT (Hs02800695_m1).  
3.10 Statistical analysis 
        Statistical significance was analyzed using Student's t-test using the statistical 
program of GraphPad Prism software (San Diego, CA). Differences between 
experimental groups were considered significant when p values were <0.05. 
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Chapter 4: Results 
	
We previously demonstrated that low concentrations of Manuka honey were 
effective in inhibiting the proliferation of several human and murine cancer cell line 
(our paper Ref). The cell lines included B16.F1 (a murine melanoma), CT26 (murine 
colorectal carcinoma) and MCF-7 (a human mammary carcinoma) [72]. For the 
current study, we focused on studying the effect of Manuka treatment on another 
human mammary carcinoma (MDA-MB231) that represents a triple-negative variant 
lacking in gene expression of estrogen and progesterone receptors and Her2/neu [60]. 
Triple-negative breast cancer carries the worst prognosis in patients [61].  
4.1 Manuka treatment inhibits human breast cancer cell growth   
We first investigated the effect of Manuka honey on the viability of MDA-
MB-231 cells. Accordingly, cells were treated with Manuka honey (at 1% or 5% w/v 
final concentration) and incubated for 12, 24 or 48 hours. As shown in Figure 6, the 
addition of 1% w/v Manuka honey to cells in culture did not result in any significant 
reduction in cell viability (92%, 97% and 88% viability, respectively). On the other 
hand, treatment with 5% manuka led to a marked reduction in cell viability, yielding 
75%, 59% and 62%, at the different time points, respectively. The inhibitory effect 
on cell viability was thus dependent on both honey concentration and total incubation 
time.  
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4.2 Manuka treatment inhibits pro-survival protein expression and increase the 
cytochrome c protein expression in human breast cancer cell  
In the next series of experiments, we addressed the potential mechanism by 
which manuka was causing a decrease in cell viability. Accordingly, we investigated 
the effect of the treatment on the Bcl-2, anti-apoptotic protein that binds to pro-
apoptotic proteins to inhibit them, and on cytochrome c, a protein located in the 
intermembrane space of mitochondria that participate in the activation of apoptosis 
upon its release in the cytosol. Therefore, MDA-MB-231 tumor cells were treated 
with 1 % or 5% of manuka honey and incubated for different time points ranging 
from 15 minutes to 12 hours. The results, shown in Figure 7, reveal significant 
decreased level of protein expression in manuka-treated cells compared to untreated 
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Figure 6. Manuka treatment inhibits human breast cancer cell growth. Cells were 
plated at 5x103 cells per well and incubated for 12 and 24 or 48 hours in the absence or presence 
of the indicated concentrations of manuka honey (1% and 5% w/v). At the end of the incubation 
period, cell viability was determined using CellTiter-Glo luminescent assay. Results are expressed 
as percentage viability in treated cell cultures compared to control, untreated, cells and are 
representative of duplicates wells. Asterisks denote statistically significant differences in viability 
of experimental groups compared to control (*, p<0.05).  
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control. Manuka treatment for 15 minutes reduced Bcl-2 protein level to 68% of 
control. A further inhibition of Bcl-2 protein expression is seen after 0.5, 0.75, 1 and 
4 hours of Manuka incubation to 22%, 26%, 24% and 21%, respectively. By 
contrast, after 6 and 12 hours of treatment the protein level of Bcl-2 starts to recover 
slightly to 45% and 37%, compare to the earlier times points. Overall, Manuka 
treatment resulted in a decrease in anti-apoptotic Bcl-2 protein in MDA-MB-231 
cancer cells.  
 
  
Figure 7. Manuka treatment decreases anti-apoptotic Bcl-2 protein in MDA-MB-
231. Cells were seeded at 4x106 cells per plate and incubated for 0.25, 0.5, 0.75, 1, 4, 6 and 12 hours 
in the absence or presence of 1 % (w/v) manuka honey. Whole cell extracts were prepared after 
indicated time points. Protein extracts (60µg/lane) were resolved on 10% SDS-PAGE and 
immunoblot with Bcl-2-specific monoclonal antibody. The cell extracts were also probed with an 
antibody against β-actin as a control for protein loading. The numbers below the blot indicate changes 
in band intensity, as determined by densitometric analysis ImageJ. The results are representative of 
two independent experiments.  
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These findings prompted us to study the impact of Manuka treatment on the 
expression of cytochrome c, a pro-apoptotic mediator. As illustrated in Figure 8, the 
immunoblot analysis shows a time and concentration dependent increase in the total 
protein expression of cytochrome c following Manuka treatment. Remarkably, the 
1% Manuka treatment did not induce significant release of cytochrome c at all time 
points (from 6 to 48 hours). However, incubation of MDA-MB-231 cells with 5% 
Manuka honey induced a marked increase in cytoplasmic cytochrome c levels (202% 
of untreated control at 6 hours). This trend continued with increasing times of 
incubation reaching 298%, 361%, and 283% of control at 12, 24, and 48 hours, 
respectively.  
 
Figure 8. Manuka treatment increases the total protein expression level of 
cytochrome c in MDA-MB-231. A. Cells were seeded at 4x106 cells per plate and incubated 
for 6, 12, 24 and 48 hours in the absence or presence of 1 % and 5% (w/v) Manuka honey. Whole 
cell extracts were prepared after indicated time points. Protein extracts (80µg/lane) were resolved 
on 10% SDS-PAGE and immunoblotted with cytochrome c specific monoclonal antibody capable 
of detecting cytochrome c protein. Cell extracts were also probed with an antibody against β-actin 
as a control for protein loading. The numbers below the cytochrome c blot indicate changes in band 
intensity, as determined by densitometric analysis ImageJ. The results are representative of two 
independent experiments.  
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4.3 Effect of Manuka treatment on STAT3 signaling pathway  
	
We next examined how Manuka honey treatment lead to the loss of viability 
in cancer cells. Of particular interest is identification of the earliest molecular targets 
of Manuka honey in the triple negative MDA-MB-231 human breast cancer cell line. 
MDA-MB-231 cells are known to express constitutively activated STAT3 [73]. 
STAT3 is transcription factor that is often observed constitutively phosphorylated on 
tyrosine, and thus activated, in numerous human malignant tumors. The constitutive 
activation of STAT3 leads to the dysregulation of various signaling pathways 
associated with oncogenesis. These pathways play critical roles in cellular 
transformation, proliferation and the suppression of apoptosis. Accordingly, we 
chose to examine the effect of Manuka honey on STAT3 phosphorylation in MDA-
MB-231 cells. Two variables were considered in the course of the treatment: 
incubation time and Manuka honey concentration. As early as 15 minutes after 
incubation with 1% (w/v) Manuka solution, the level of STAT3 tyrosine 
phosphorylation was reduced by 54% compared to the levels observed in untreated 
cells, Figure 4A. The inhibition of STAT3 phosphorylation persisted for at least 6 
hours but returned to normal levels by 12 hours. The degree of inhibition and 
duration of phospho-STAT3 were more pronounced in cells treated with 5% Manuka 
solution (Fig. 9B, D). Importantly, Manuka treatment had no effect on total STAT3 
protein levels at any of the time points examined (Fig. 9A). This rules out any 
influence of the treatment on STAT3 gene transcription or translation. 
	
31	
	
	
	
	
 
Mol.weight  
(KDa) 
C 0.25 
Manuka incubation time (Hr) 
0.5 0.75 1 4 6 12 
45  β-actin 
79,86 STAT3 
79,86 p.STAT3 Tyr   
A 
1.00 0.46 0.24 0.25 0.23 0.15 0.14 0.85 
1.00 0.78 0.78 1.05 0.99 0.88 0.85 0.83 
Co
ntr
ol
0.2
5 0.5 0.7
5 1 4 6 12
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
Re
la
tiv
e 
De
ni
st
y
*
*** *** ** *
1% Manuka Treatment 
B 
32	
	
	
	
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C 
Mol.weight  
(KDa) 
C 0.25 
Manuka incubation Time (Hr) 
0.5 0.75 1 4 6 12 
45  β-actin 
79,86 p-STAT3 Tyr 
1.00 0.32 0.18 0.11 0.08 0.04 0.08 0.36 
1.00 
STAT3 
0.84 0.66 0.45 0.65 0.43 0.55 0.47 
79,86 
Co
ntr
ol
0.2
5 0.5 0.7
5 1 4 6 12
0.0
0.2
0.4
0.6
0.8
1.0
Re
lat
ive
 D
en
ist
y
** *
*** *** ***
**
*
5% Manuka Treatment 
D 
Figure 9. Manuka treatment reduces the STAT3 Tyrosine phosphorylation in a time and 
dose-dependent manner. A. Cells were seeded at 4x106 cells per plate and incubated for 0.25, 0.5, 
0,75,1,4,6 and 12 hours in the absence or presence of 1 % (A) and 5% (C) (w/v) Manuka honey. Whole 
cell extracts were prepared after indicated time points. Protein extracts (60µg/lane) were resolved on 10% 
SDS-PAGE and immunoblotted with STAT3-Tyr-specific (A & C) and STAT3 monoclonal antibody 
capable of detecting STAT3-Tyr phosphorylated protein and STAT3 total protein. The cell extracts were 
also probed with an antibody against β-actin as a control for protein loading. The numbers below the 
STAT3 blot indicate changes in band intensity, as determined by densitometric analysis ImageJ. B &D. 
Relative density of p-STAT3 Tyr protein expression in 1% (B) and 5% (D) Manuka treatment is 
representing of two independent experiments. Asterisks denote statistically significant differences in 
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Next, we were interested to investigate whether Manuka honey could inhibit other 
targets that are dependent on tyrosine phosphorylation for their activation. Tyrosine 
phosphorylation is an important mechanism of signal transduction that regulates 
many essential signaling pathways in eukaryotic cells [74]. Therefore, we looked at 
the total tyrosine phosphorylation pattern of Manuka-treated cancer cells. As shown 
in Figure 5, Manuka treatment of either concentration 1% (Fig. 10A) and 5% (Fig. 
10B) did not alter the gross cellular tyrosine phosphorylation pattern. 
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Figure 10. Manuka treatment does not alter the gross cellular tyrosine 
phosphorylation pattern. A. Cells were seeded at 4x106 cells per plate and incubated for 
0.25, 0.5, 0,75,1,4,6 and 12 hours in the absence or presence of 1 % (A) and 5% (B) (w/v) 
Manuka honey. Whole cell extracts were prepared after indicated time points. Protein extracts 
(60µg/lane) were resolved on 10% SDS-PAGE and immunoblotted with P-Tyr-1000 specific 
multiMab monoclonal antibody capable of detecting broad range of tyrosine-phosphorylated 
proteins and peptides. The results are representative of one independent experiment.  
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4.4 Manuka honey inhibits IL-6 production  
	
It is known that constitutive Stat3 phosphorylation in MDA-MB-231 cells 
occurs through an autocrine/paracrine loop involving continuous secretion of IL-6 
cytokine [62]. IL-6 binds to the IL-6 receptor and induces the homodimerization of 
gp130 that, in turn, triggers the JAK/STAT signaling cascade. In order to examine 
the effect of Manuka treatment on IL-6 production, cells were co-treated with 
Brefeldin A, a protein transport blocker, to keep IL-6 protein inside the cells and 
thereby be detected by western blot analysis. Figure 11 demonstrates clearly the 
ability of Manuka honey to inhibit the production of IL-6. At 4.5 hours of Manuka 
treatment with 1% or 5% concentration, a significant decrease in the total level of IL-
6 was observed, amounting to 41 % and 17 %, respectively, of the cytokine levels in 
untreated control.  
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Figure 11. Manuka Treatment inhibits IL-6 production. A. Experimental procedure. 
B. Cells were seeded at 4x106 cells per plate and then co-treated with 1 % and 5% (w/v) Manuka 
honey and Brefeldin A for 4 hours. Whole cell extracts were prepared after indicated time point. 
Protein extracts (80µg/lane) were resolved on 10% SDS-PAGE and immunoblotted with IL-6-
specific monoclonal antibody capable of detecting IL-6 total protein. Cell extracts were also 
probed with an antibody against β-actin as a control for protein loading. The numbers below the 
IL-6 blot indicate changes in band intensity, as determined by densitometric analysis ImageJ. 
The results are representative of two independent experiments. 
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4.5 Heat treatment of Manuka honey abrogates its STAT3 dephosphryation 
activity  
Next, we investigated the characteristics of the active compound/s in Manuka 
honey that cause the dephosphorylation of STAT3. Therefore, we examined the 
effect of boiled honey on MDA-MB-231 cells, specifically on Tyr phospho-STAT3 
and total STAT3 protein levels. As shown in Figure 12A, there was no alteration in 
total STAT3 protein levels following incubation with heat-treated Manuka solution. 
Surprisingly, inhibition of pSTAT3 was abrogated after incubation with 1% or 5% 
heat-treated Manuka honey. We also examined the effect of heat-treated Manuka 
honey on the expression level of Bcl-2. Heat-treated Manuka honey had no effect on 
Bcl-2 level regardless of the concentration, in sharp contrast to the >70% inhibition 
observed when fresh Manuka honey solution was used (Fig. 12A). In a further 
experiment, cell extracts were prepared after treatment with either fresh or heat-
treated 5% Manuka solution. As demonstrated in Figure 12B, treatment with heat-
treated Manuka honey for 30 minutes resulted in 92% pSTAT3 Tyr protein 
expression level compared to control. On the other hand, the 5% treatment with 
normal Manuka honey for 30 minutes resulted in 69% pSTAT3 Tyr protein 
expression level compare to the control 100%. 
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Figure 12. Heat treatment of Manuka honey losses its inhibitory effect on STAT3 
phosphorylation. A&B. Cells were seeded at 4x106 cells per plate and incubated for 30 minutes 
in the absence or presence of heat-treated 1 % and 5% (w/v) Manuka honey and normal (unheated) 
1 % and 5% (w/v) manuka honey. Whole cell extracts were prepared after indicated time points. 
Protein extracts (60µg/lane) were resolved on 10% SDS-PAGE and immunoblotted with STAT3, 
pSTAT3 Tyr and Bcl-2 specific monoclonal antibody. Cell extracts were also probed with an 
antibody against β-actin as a control for protein loading. The numbers below the blot indicate 
changes in band intensity, as determined by densitometric analysis ImageJ. The results are 
representative of one independent experiment. 
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4.6. STAT3 dephosphorylation is not due to the induction of SOCS3  
STAT3 activation is controlled by several post-translational mechanisms. 
One of these mechanisms is the induction of negative feedback phosphatases, 
enzymes that are capable of removing phosphate groups from their substrates. 
Therefore, we hypothesized that the loss of STAT3 phosphorylation could be due to 
the induction of tyrosine phosphatases. Suppressor of cytokine signaling 3 (SOCS3) 
is an inhibitor that acts as a negative feedback loop in the classical STAT3/JAK2 
signaling pathway. SOCS3 expression is induced via IL-6 stimulation and functions 
as an inhibitor of cytokine receptor phosphorylation by interfering with JAK2 kinase 
activity, thereby preventing further downstream signaling pathway activation [75]. 
Therefore, we investigated the effect of Manuka honey treatment on SOCS3 total 
protein level. As shown in Figure 13, SOCS3 protein expression level did not differ 
between control and treated groups. At 0.25, 0.5, 0.75, 1 and 4 of Manuka treatment 
the expression level of SOCS3 are 109%, 119%, 124%, 84% and 98%, respectively. 
However, at 6 and 12 hours post treatment SOCS3 protein level increased to 167% 
and 264% respectively, compared to untreated control. 
	
	
	
Figure 13. STAT3 dephosphorylation is not due to SOCS3. Cells were seeded at 4x106 
cells per plate and incubated for 0.25, 0.5, 0,75,1,4,6 and 12 hours in the absence or presence of 1 % 
(w/v) Manuka honey. Whole cell extracts were prepared after indicated time points. Protein extracts 
(60µg/lane) were resolved on 10% SDS-PAGE and immunoblotted with SOCS3-specific monoclonal 
antibody capable of detecting SOCS3 total protein. Cell extracts were also probed with an antibody 
against β-actin as a control for protein loading. The numbers below the SOCS3 blot indicate changes 
in band intensity, as determined by densitometric analysis ImageJ. The results are representative of 
one independent experiment. 
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Furthermore, we examined gene expression levels of SOCS3 and two other proteins 
known to regulate STAT3 activity, protein tyrosine phosphatase non-receptor type 2 
(PTPN2) and protein inhibitor of activated STAT3 (PIAS3) by qRT-PCR. No 
consistent pattern of alterations in the expression of any of the three genes could be 
observed (Figure 14). Maximal induction of ~2-fold over non-treated cells was 
observed in SOCS3 after 1 hour of treatment with 1% Manuka honey. For PIAS3 and 
PTPN2, minimal changes in gene expression were observed throughout the treatment 
period.  
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Figure 14. Manuka treatment effect PIAS3, SOCS3 and PTPN1 differently. Cells were 
seeded 4x106 cells per plate and incubated for 0.25, 0.5, 0,75,1,4,6 and 12 hours in the absence or 
presence of 1 % (w/v) Manuka honey. Each treatment group were seeded in duplicates. Then RNA 
were isolated and converted to cDNA to be analyzed by quantitative real-time PCR for three genes, 
PIAS3, SOCS3 and PTPN1. The results are representative of two independent experiments. 
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4.7. Inhibition of oncoprotein c-Myc by Manuka honey treatment 
STAT3 targets several transcription factors that can promote cell growth, 
proliferation and survival; c-myc gene is one of these targets. The proto-oncogene c-
myc encodes two proteins: p64 and p67, which together form the c-Myc transcription 
factor that binds to DNA and activates gene expression [79]. Abnormal expression of 
c-Myc has been associated with the initiation and progression of many malignances. 
Therefore, we examined the consequences of Manuka-mediated STAT3 
dephosphorylation on c-Myc protein expression level. As shown in Figure 15, 
Manuka treatment led to a dramatic decrease in c-Myc, protein, to 78%, 61% and 
27% at 0.25, 0.5 and 0.75 hours of treatment.	However, after 1 and 4 hours post 
treatment c-Myc protein level reached to 77% and 85%, resepectivly, then followed 
by significant decreased to 12% at 6 hours of treatment. Finaly, at 12 hours of 
Manuka treamtment c-Myc proien level recovered to 95%.  
	
Figure 15. Inhibition of oncoprotein c-Myc p67 by Manuka honey treatment. Cells were 
seeded at 4x106 cells per plate and incubated for 0.25, 0.5, 0,75,1,4, 6 and 12 hours in the absence or 
presence of 1 % (w/v) Manuka honey. Whole cell extracts were prepared after indicated time points. 
Protein extracts (60µg/lane) were resolved on 10% SDS-PAGE and immunoblotted with c-Myc p68-
specific monoclonal antibody capable of detecting c-Myc p68 total protein. Cell extracts were also probed 
with an antibody against β-actin as a control for protein loading. The numbers below the c-Myc blot 
indicate changes in band intensity, as determined by densitometric analysis ImageJ. The results are 
representative of two independent experiments. 
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4.8. Manuka honey reduced NF-kappa-B-P65 activity in MDA-MB-231 cancer 
cells  
RELA/NFκB/p65 is one of the most important members in the NF-kappa B 
family. It has been found that it regulates many genes in tumorigenesis, survival, and 
proliferation. Serine phosphorylation at position 536 is an indicator of 
RELA/NFκB/p65 activation and nuclear translocation. Since we found that Manuka 
honey inhibits significantly the activity of STAT3, we predicted that it might inhibit 
NFκB similarly. Therefore, our goal in this experiment is to examine the effect of 
Manuka honey treatment on NFκB total protein and its transcriptional activity. As 
illustrated in Figure 16, the level of total NFκB did not differ significantly between 
the untreated and treated groups. At 0.25, 0.5, 0.75, 1,4 and 6 of Manuka treatment 
the expression level of NFκB are 89%, 94%, 96%, 73%, 86% and 76%, respectively. 
However, the level of serine phosphorylated NFκB have decreases as early as 15 
minutes post-Manuka treatment to 56% compare to the untreated that is considered 
100%. Similarly, at 0.5, 0.75 and 1 hour’s post-Manuka honey treatment, the 
phospho-NFκB (Ser536) was maintained reduced to 49%, 59% and 50%, 
respectively. However, at 4 and 6 hours the protein level starts to recover and 
increase to 78% and 145%, respectively.  
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Figure 16. Manuka honey decreased nuclear factor NF-kappa-B-P65 activity in MDA-MB-
231 cancer cells. Cells were seeded at 4x106 cells per plate and incubated for 0.25, 0.5, 0,75,1,4 and 6 hours 
in the absence or presence of 1 % (w/v) Manuka honey. Whole cell extracts were prepared after indicated time 
points. Protein extracts (80µg/lane) were resolved on 10% SDS-PAGE and immunoblotted with NFκΒ and 
NFκΒ (Ser536) -specific monoclonal antibody capable of detecting NFκΒ total protein and serine 
phosphorylated NFκΒ. The cell extracts were also probed with an antibody against β-actin as a control for 
protein loading. The numbers below the blot indicate changes in band intensity, as determined by densitometric 
analysis ImageJ. The results are representative of two independent experiments. 
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Chapter 5: Discussion 
	
We have previously demonstrated that Manuka honey has the capacity to 
inhibit the proliferation of several types of murine and human cancer cell lines in a 
time- and dose-dependent manner in mammary carcinoma [72]. Moreover, the anti-
proliferative effect of manuka honey was mediated, at least in part, by the induction 
of the intrinsic pathway of apoptosis [72]. For the current study, we focused on 
investigating the molecular effect of Manuka treatment on a human mammary 
carcinoma called MDA-MB-231, which is a triple-negative breast cancer (TNBC) 
cell line that lacks gene expression of estrogen and progesterone receptors and 
Her2/neu. TNBCs are the most aggressive and difficult to treat type of breast 
cancers, with high rates of p53 mutations, constitutive activation of the IL-6/STAT3 
signaling pathway, and increased resistance to chemotherapy [61].    
Constitutively activated STAT3 results in disrupted cell signaling that promotes cell 
proliferation and inhibits apoptosis. This activation drives many proto-oncogenic 
pathways that promote cellular oncogenesis. STAT3 plays a pivotal role as a central 
mediator in many major cell signaling pathways in the human TNBC cell line MDA-
MB-231, promoting growth and survival. We have hypothesized that Manuka honey 
may block the activity of STAT3 and hence its gene transcriptional activity. 
Consequently, the multiple signaling pathways regulated by this transcription factor, 
including apoptosis, may well be affected by treatment with Manuka honey.  
 The findings presented herein identify STAT3 as one of the earliest proteins targeted 
by Manuka treatment. Inhibition of STAT3 activity by Manuka treatment occurs 
through its dephosphorylation at a critical tyrosine residue (Tyr705) that renders 
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STAT3 inactive. There is no evidence that Manuka treatment had any effect on the 
total STAT3 protein levels, excluding any influence of the treatment on STAT3 gene 
transcription. Instead, Manuka treatment appears to principally inhibit the level of 
tyrosine phosphorylation of STAT3 and, consequently, its ability to function as a 
transcription factor. 
To address the proposed hypothesis, MDA-MB-231 cells were exposed to a low 
concentration of Manuka honey (1% w/v) that has previously been shown not to 
cause any significant cell death. This was done in order to observe any interruption 
of cell signaling pathways without interference by any of the cell death pathways. 
These studies demonstrated a significant suppression of STAT3 activity that was 
observable as early as 15 minutes post-exposure to Manuka honey. The inhibition in 
STAT3 tyrosine phosphorylation persisted for at least 6 hours after exposure to 1% 
Manuka solution but, importantly, without any affect on total STAT3 protein levels. 
Moreover, the degree and the extent of duration of phospho-STAT3 inhibition were 
more pronounced in cells exposed to 5% Manuka solution compared to 1% solution. 
This suggested that the concentration of the active component(s) present in the 
Manuka honey that acted on STAT3 dephosphorylation was important to achieve 
longer duration suppression. In addition, the treatment did not affect the total protein 
level of STAT3, but rather reduced its activity only through tyrosine 
dephosphorylation. Interestingly, the total tyrosine phosphorylation profile in 
western blot analysis showed no significant changes upon treatment with either 1% 
or 5% Manuka solution, suggesting that Manuka honey could be selectively 
inhibiting STAT3 tyrosine phosphorylation. 
46	
	
	
	
	
Human MDA-MB-231 TNBC cells depend on constitutive STAT3 activity for their 
survival through the induction of anti-apoptotic proteins. The inhibition of upstream-
activated tyrosine kinases such as Src and JAK2, known kinases that activates 
STAT3, were found to block STAT3 signaling and result in cell growth inhibition 
[62]. Conversely, the inhibition of these kinases in cells that do not express 
constitutive pSTAT3, had no effect on their cell growth kinetics [76]. Our current 
findings demonstrate that exposure of MDA-MB-231 human breast cancer cells to 
Manuka honey is accompanied by a significant decrease in the pro-survival proteins 
Bcl-2 and increased cytochrome c protein expression level. This may well be linked 
to the ability of Manuka honey to suppress STAT3 activity in these cells thereby 
inhibiting its function as a transcription factor that upregulates the expression of pro-
survival proteins and, hence, promoting cellular resistance to apoptosis.  
One of the important target genes for the STAT3 transcription factor is c-Myc, a 
major oncogene that drives cell cycle progression and proliferation. In fact, many 
studies indicated that persistent STAT3 activity is associated with increased level of 
cell cycle regulator proteins, such as cyclin D1 and c-Myc [9, 78]. In one study, 
HepG2 cells (human liver hepatocellular carcinoma), pre-transfected with human c-
myc and luciferase genes, were used to investigate IL-6-induced gene expression 
[79]. The study demonstrated that increased activation of c-myc RNA expression was 
due to IL-6/gb130/STAT3 signaling pathway. Since STAT3 is involved in 
transmitting signals mediated by IL-6 stimulation, expression of a dominant negative 
STAT3 abolished IL-6 mediated c-myc RNA expression. Moreover, a site in the c-
myc promoter region, called E2F site, was identified as the binding site for STAT3 
[79], confirming the causal link between STAT3 and c-Myc oncogene. 
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It is noteworthy that in our system, exposure of MDA-MB-231 cancer cells to 
Manuka honey also led to an inhibition of c-Myc protein expression. The inhibition 
was maximal at 6 hours post-exposure and followed the reduction in phospho-
STAT3, which was evident as early as 15 minutes after Manuka honey treatment. 
Taken together, Manuka honey-induced inhibition of STAT3 transcriptional activity 
also resulted in a reduction of c-Myc protein expression, which accounts for the 
observed growth suppression in treated MDA-MB-231 cells. 
There is a growing body of evidence that suggests that constitutively activated 
STAT3 represents an oncogenic signal in various cell types [80]. In the murine 4T1 
TNBC cell line, STAT3 knockdown suppressed the cells’ invasiveness in vitro and 
blocked their ability to induce mammary breast tumor and to metastasize in 
immunocompetent mice [81]. In a separate study, it was demonstrated that rodent 
fibroblasts transformed by the src oncogene expressed constitutively active STAT3 
and the loss of this activity prevented src from inducing cellular transformation in 
fibroblast cell lines [82]. Furthermore, there is evidence that the presence of activated 
STAT3 molecule by itself can lead to cellular transformation [65, 83, 84]. 
Transfection of different cell lines with an engineered, persistently dimerzeable 
STAT3 molecule, called Stat3-C, demonstrated the ability of this molecule to induce 
constitutive transcriptional signals that were almost equal to those in v-src 
transformed cell line [84]. In addition, nude mice injected with 106 Stat3-C- 
transfected primary rat fibroblast cells (called 3Y1 cells) developed tumors 2 to 3 
weeks post-injection. In sharp contrast, nude mice injected with the 3Y1 parental cell 
line did not develop any tumors over 8 weeks of observation period [84]. The pro-
oncogenic capability of STAT3 is thought to be due to its ability to regulate the 
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transcription of many critical genes that play important roles in cell cycle 
progression, survival, inflammation, angiogenesis, invasion and metastasis [84]. 
The potential mechanism by which Manuka honey treatment leads to STAT3 
dephosphorylation was also investigated in this study. Sustained activation of STAT3 
would require (1) an upstream mutant tyrosine kinase that resists dephosphorylation 
or (2) continuously activated receptor-tyrosine kinase complexes or (3) a constitutive 
ligand stimulation that creates autocrine or paracrine loop activation (Fig.17). The 
precise mechanism underlying constitutively active STAT3 depends on the tumor 
type as well as the cellular context.  
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gene expression. This might provide an explanation as
to why normal cellular growth, as well as tumour devel-
opment, can occur without mutations in p53 or in pro-
teins that interact with p53, such as ARF and MDM2
(G. Niu and H.Y., unpublished observations).Although
TP53 mutations occur in about half of human cancers,
and mutations that disrupt ARF and MDM2 function
have been implicated in some cancers, many cancers do
not have these mutations but instead show reduced p53
expression. For example, 80% of breast tumours exam-
ined were found not to contain TP53 mutations,
although TP53 expression was downregulated at the
RNA level75. Importantly, p53 functions can be restored
in cancer cells by inhibiting STAT3 signalling, thereby
inducing p53-mediated cancer-cell apoptosis (G. Niu
and H.Y., unpublished observations). This offers an
exciting and novel approach for restoring p53 function
in a variety of cancer cells that express low levels of p53.
A potential role for STAT5 in negatively regulating TP53
gene expression has not yet been explored.
Role of STATs in tumour angiogenesis
The intrinsic ability ofa cancer cell to proliferate uncon-
trollably and resist apoptosis is often required, but not
sufficient, for tumour development. During organogen-
esis, all cells in a tissue must reside within close proximity
of a capillary76. Similarly, most tumours cannot sustain
their growth unless they are supplied with oxygen and
nutrients from newly formed blood vessels, and a crucial
role of activated oncogene products in stimulating
angiogenesis has been established8,77–79. The most potent
angiogenesis-inducing signal is vascular endothelial
growth factor (VEGF)80–82.Compared with their normal
counterparts, cancer cells produce increased levels of
VEGF,which binds to transmembrane receptor tyrosine
kinases of endothelial cells.This activates endothelial-cell
migration and proliferation, which is necessary for the
formation of new blood vessels83,84.
Recently, STAT3 has been shown to be a direct tran-
scriptional activator of the VEGF gene85,86 (FIG. 4).
Transfection of cells with the constitutively activated
mutant STAT3C is sufficient to increase VEGFexpression
and induce angiogenesis in vivo85. Blocking STAT3 sig-
nalling has been shown to inhibit SRC and IL-6-induced
VEGFupregulation85,87, and might therefore also abrogate
the induction of VEGF by many other tyrosine-kinase
pathways that lie upstream of STAT3.Earlier studies sug-
gested that the hypoxia-inducible factor 1 (HIF1),a tran-
scription factor that controls oxygen homeostasis, is the
final switch for VEGF upregulation in cancer88,89.Oxygen
deprivation due to intratumoural hypoxia and activation
of signal-transduction pathways can both lead to HIF1
activity88,89. In addition,a crucial role of p53 in regulating
the stability of HIF1-α— the inducible subunit of HIF1
— is well established90. Because STAT3 inhibits p53
expression (G.Niu and H.Y.,unpublished observations),
interruption of STAT3 signalling is also expected to lower
HIF1 activity by promoting its degradation through p53-
dependent mechanisms. STAT3 inhibitors might there-
fore block VEGF expression at several levels,generating a
potent anti-angiogenic effect.
it has been shown that c-MYC expression is downregu-
lated by IFN-γ, which activates STAT169. In addition,
many growth-factor signalling pathways are known to
regulate cell proliferation by enhancing the activity of
cyclins, contributing to accelerated cell-cycle progres-
sion. Constitutive activation of STAT3 is associated with
cyclin D1 upregulation, and STAT5 activity has been
shown to promote the expression of cyclin D236,70–73. It is
important to note that the extent to which cells depend
on STAT3 and STAT5 to regulate genes that control cell
proliferation and survival varies among different
tumour types12,17 — this is likely to be due to cell-type-
specific differences in STAT-interacting proteins, such as
other transcription factors11,21. In most cases, it remains
to be shown at the chromosomal level that candidate
target genes are directly regulated by STAT3 or STAT5.
The p53 protein is considered to be the most wide-
spread inhibitor of cell proliferation and inducer of
apoptosis because of its ability to integrate signals from
a variety of sources and to activate numerous genes that
are crucial for growth arrest and apoptosis74. Recent
studies have shown that normal growth and oncogenic
signalling pathways use STAT3 to downregulate TP53
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Figure 2 | Signalling pathways that converge on STATs. STATs are an important point of
convergence for many signalling pathways that are commonly activated in cancer cells. Binding
of growth factors or cytokines to their receptors results in the activation of intrinsic receptor-
tyrosine-kinase activity or of receptor-associated kinases, such as the Janus kinase (JAK) or SRC
tyrosine kinases. These tyrosine kinases subsequently phosphorylate the cytoplasmic tails of the
receptor to provide docking sites for the recruitment of monomeric STATs. Once they have been
recruited, STATs themselves become substrates for tyrosine phosphorylation. Non-receptor
tyrosine kinases, such as the oncoproteins SRC and BCR–ABL (a fusion of the breakpoint-cluster
region (BCR) and Abelson leukaemia (ABL) proteins), can phosphorylate STATs independently of
receptor engagement. Phosphorylated STATs dimerize and translocate to the nucleus, where the
dimers directly regulate gene expression. Whereas STAT activation is tightly regulated in normal
cells, the persistent activation of tyrosine kinases in cancer causes constitutive activation of STATs
— in particular STAT3 and STAT5. This leads to permanent changes in the expression of genes
that control fundamental cellular processes, which are subverted in cancer cells. Dashed arrows
indicate the ‘recycling’ of STAT proteins from the nucleus to the cytoplasm.
© 2004 Nature Publishing Group
Figure 17: Mechanisms of STAT3 signaling. Obtained from: Jove et 
al., The STATs f cancer — new molec lar targets come of age, 
Nature Reviews Cancer 4, 97-105 (2004).  
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It was previously established that in MDA-MB-231 cells, the hyperactivated STAT3 
phosphorylation is maintained through IL-6-mediated gp130 cytokine receptor-
tyrosine kinase complex signaling. It has been demonstrated that the inhibition of the 
tyrosine kinases Src or the epidermal growth factor receptor, had no effect on STAT3 
tyrosine phosphorylation level in MDA-MB-231 breast cancer cells. However, 
inhibition of Jak2 or the gp130 cytokine receptor resulted in suppressed STAT3 
tyrosine phosphorylation in these cells. In addition, IL-6 sequestration also resulted 
in decreased level of STAT3 activity, confirming the critical role of autocrine 
signaling through the IL-6/gp130/JAK2/STAT3 pathway in maintaining STAT3 in a 
functionally activated state [62].  
Accordingly, we investigated the effect of Manuka treatment on IL-6 production by 
MDA-MB-231 cells. Our findings confirmed that exposure of cancer cells to 
Manuka honey resulted in a dramatic decrease in IL-6 production. The degree of 
inhibition in IL-6 production was dependent on the final concentration of manuka 
honey used in the treatment, with ~59% and 83% inhibition being observed with 1% 
and 5% (w/v) Manuka honey, respectively. Since autocrine stimulation by IL-6 is the 
main factor in maintaining STAT3 activation in MDA-MB-231 human breast cancer 
cells, Manuka treatment appears to block the autocrine IL-6/STAT3 positive 
feedback loop.  
Further investigation is needed to clarify if treatment with Manuka honey also 
suppresses JAK2 tyrosine kinase activity or reduces the expression level of IL-6 
cytokine receptor on MDA-MB-231 cancer cells. Nevertheless, our findings to date 
allow us to present a simplified diagram to illustrate the molecular targets of Manuka 
honey (See Figure 18).  
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Figure 18: Diagram of Manuka honey molecular targets 
 
It is known that the activity of STAT3 is regulated at the post-translational level by 
tyrosine kinases and phosphatases as well as by inhibitors [75]. Among the inhibitor 
known to act on the STAT3 signaling pathway are SOCS3 and PIAS3 [85]. Like 
STAT3, the SOCS-3 inhibitor is also induced by IL-6 family cytokines and binds 
directly to the kinase region of JAK2 blocking its interaction with, and hence the 
phosphorylation of, gp130 cytokine receptor [86].  In contrast, PIAS3 has been 
shown to bind to STAT3 dimers in the nucleus and prevent their binding to DNA, 
thereby blocking STAT3 target gene transcription [87]. It is known that PIAS3 is 
also subject to cytokine-dependent activation and appears to be a specific inhibitor of 
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STAT3 without any effect on other STAT proteins [85]. On the other hand, PTPN1 
has the ability to translocate to the nucleus and dephosphorylate activated STAT3 
dimer [74]. Therefore, it was important to determine whether Manuka treatment had 
any effect of the expression levels of these STAT3 regulators. Our findings 
demonstrate that exposure to Manuka honey does not alter mRNA or protein 
expression levels of SOCS3, PTPN1 or PIAS3 in MDA-MB-231 cells. These results 
suggest that the observed Manuka honey-mediated inhibition of STAT3 is 
independent of all of the above regulatory proteins. In a recent study, the effect of 
flavone, a plant flavonoid, on STAT3 activity was investigated in human vascular 
endothelial cells that lack SOCS3 gene expression [88]. The findings of this study 
showed that flavone was able to reduce STAT3 tyrosine phosphorylation despite the 
absence of SOCS3, confirming that STAT3 regulation can occur independently of 
SOCS3 [88]. It is noteworthy that, in this study, human vascular endothelial cells 
were also shown to produce IL-6, which was responsible for maintaining STAT3 
hyperactivity in these cells. Similar to our findings with Manuka honey, flavone was 
able to interrupt cytokine-induced STAT3 activation [88]. We conclude that Manuka 
honey blocks the production of IL-6 and interrupts STAT3 tyrosine phosphorylation 
in human breast cancer cells.  
Next, we were interested to characterize the chemistry of the active components in 
Manuka honey responsible for STAT3 dephosphorylation. We decided to study the 
effect of temperature on Manuka honey’s ability to inhibit the expression of STAT3 
and pro-survival protein Bcl-2. Our findings demonstrated that heating of Manuka 
honey solution(1% or 5% w/v) neutralized the active Manuka honey component(s) 
responsible for STAT3 dephosphorylation. Likewise, there was no reduction in the 
level of Bcl-2 following exposure of MDA-MB-231 cells to heat-treated Manuka 
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honey, suggesting that the active component(s) responsible for the observed cellular 
inhibition is heat-sensitive. A previous study reported the capacity of Manuka honey 
to induce pro-inflammatory cytokine production by human monocytic cells [57]. 
This activity was also abolished upon boiling of the unfractionated Manuka honey 
solution, suggesting that the active component(s) responsible for this induction is 
also heat sensitive [57]. The precise components of Manuka honey that mediate these 
various effects on cancer cells and monocytes remain unknown. 
In a recent review, the effect of temperature on phytochemicals was reported to have 
two contrasting consequences: 1) heat-induced degradation, thus decreased 
concentration, of phytochemicals or 2) increase in the extractability of 
phytochemicals [89]. The outcome is dependent on the structure of the food matrix 
and chemical nature of the specific compound [89]. It has been demonstrated that 
temperature in the range of 90°C to 150°C results in reduced antioxidant activity of 8 
different phenolic acids, and a linear relationship was found between increasing 
temperature and the antioxidant activity [90]. For example, a study investigated the 
effect of different cooking techniques on quercetin, one of the flavonoids, content in 
onions and tomatoes and found that a loss of 75-80% in quercetin concentration was  
evident after boiling for 15 minutes [91]. According to Ayurveda, holistic healing 
system developed in India a thousand years ago, heating the honey leads to a loss in 
its nutraceutical (nutritional and pharmaceutical) properties [92]. Furthermore, 
enzymes present in the honey such as invertase and diastase begin to lose their 
activity after 55°C heating treatment [93], and after 100°C total enzymatic 
inactivation has been reported [94]. Taken together, the findings of all the above 
studies confirm the deleterious effect of heat treatment on phytochemical content and 
enzymes present in food.      
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IL-6/gp130/JAK2/STAT3 signaling is a crucial pathway that regulates 
tumorigenesis, survival, chemotherapy resistance, immune invasion and metastasis 
[63, 69, 95]. Each component of this pathway has been targeted and proven its 
effectivity against a wide range of cancers [67]. The presence of IL-6 and STAT3 
were significantly correlated with high-grade breast cancer that was resistant to 
chemotherapy and considered to have poor prognosis [73]. The involvement of IL-6 
in cancer progression and invasion has been found in every type of cancer (see Table 
2), underscoring the importance of IL-6 as a therapeutic target. More importantly, all 
of these studies confirmed the presence of STAT3 that converge the signals from IL-
6 stimulation.  
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Type of cancer Effect of IL-6 Reference(s) 
Breast Regulate VEGF expression and 
promoting tumor growth and 
metastasis 
 
[96, 97] 
Glioma  Promote malignant formation 
and progression and induce 
VEGF transcription 
[98, 99] 
Chronic Lymphocytic 
Leukemia 
Worse median survival and 
treatment outcome  
[100] 
Lung  Increase cell proliferation  [101] 
Lymphoma  Adverse disease outcome, poor 
survival and its inhibition 
reduced lymphoma growth 
[102, 103] 
Melanoma  Elevated tumor burden and 
failure to response to bio-
chemotherapy 
[104] 
Multiple Myeloma  Stimulate cell proliferation  [105] 
Ovarian  Promote inflammatory cytokine 
production, angiogenesis and 
immune invasion 
[106] 
Table 2: IL-6 and cancer 
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Several factors contributed to the emergence of STAT3 as a promising molecule for 
therapeutic intervention. Firstly, its acts as a central converge of three main signaling 
pathways known to enhance oncogenesis: Src non-receptor tyrosine kinase, 
epidermal growth factor receptor and IL-6/cytokine receptor. Secondly, the activity 
of STAT3 regulates a wide range of genes that affect cancer at multiple levels, such 
as malignant progression, invasion, angiogenesis, survival, chemotherapy resistance 
and immune evasion (see Fig.19) [65]. Thirdly, studies done in normal mouse 
fibroblasts have showed that suppressing STAT3 signaling is not lethal in normal 
cells growth, because normal cells are not totally dependent on STAT3 signaling and 
are capable to use another signaling pathways to overcome the absence of STAT3 
[83, 107].  
 
 
 
 
 
 
 
 
 
 
phosphorylated STAT3 is not due to mutations in STAT3 but arises from
oversupply of growth factors, such as TGFα or (IL6-family) cytokines
within the tumor microenvironment that activate STAT3 in a paracrine
manner. The activation of oncogenes, inactivation of tumor-suppressor
genes, chromosomal rearrangement/amplification, deregulation of
multiple potential upstream inputs such as elevated EGFR expression
levels, EGFR mutations that result in c nstitutive RTK activation, over-
expression of Src or other SFKs, mutations that hyperactivate JAKs
[89] and other genetic events in neoplastic cells directly trigger
STAT3 activation or the release of inflammatory mediators as part
of an autocrine pathway [127]. Hyper-activation of STAT3 can also
result from impairment mutations in any of the negative regulatory
proteins, which limit the extent of STAT3 activation in normal cells
[128]. For example, epigenetic silencing of SOCS3 by hypermethylation
in CpG islands of the functional SOCS-3 promoter in human lung can-
cers [129] as well as mutations in STAT3-inactivating receptor protein
tyrosine phosphatase delta in glioblastoma and other human cancers
[130] leads to STAT3-mediated cell proliferation and survival.
Forced expression of a constitutively active form of STAT3 in mouse
epidermis was found to shorten latency and enhance the number of
malignant skin lesions progressing rapidly to squamous-cell carcinoma,
induced by two-stage carcinogenesis [131]. Transfection of a dominant-
negative form of STAT3 led to production of soluble factors that induce
apoptosis and cell cycle arrest in the murine melanoma model [132].
A growth promoting role for STAT3 in the mouse model of anaplastic
large cell lymphomas mediated by the oncogenic fusion protein,
nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), was dem-
onstrated in both in vitro and in vivomodels. Even though NPM-ALK-
dependent tumor could develop in the absence of STAT3, STAT3 is re-
quired for the growth and survival of NPM-ALK lymphoma T cells
in vitro and in vivo. Ablation of STAT3 in mice bearing xenografted
NPM-ALK-dependent T-cell lymphomas significantly impaired tumor
growth in vivo [133], suggesting that tumor cells formed in the presence
of STAT3 become STAT3 addicted. Moreover the growth of murine B16
melanoma cells that harbored activated STAT3 could be suppressed ef-
ficiently in mice by introduction of a functionally deficient STAT3 vari-
ant [134]. Constitutive activation of STAT3 is involved in many cellular
processes including proliferation, survival, inflammation, invasion,
metastasis and angiogenesis, all of which favor tumor initiation and
progression (Fig. 2) and have been discussed below in detail.
3.1. Proliferation
STAT proteins have been shown to play important roles in cell
proliferation induced by cytokines. The first evidence towards the
role of STAT3 in survival was that STAT3 activation is essential for
gp130-induced proliferation of the IL-3-dependent pro-B hematopoiet-
ic cell line, BAF/B03 cells [135]. In breast carcinoma cells, autocrine-
mediated STAT3 activationwas found to correlatewith cell proliferation
[136]. Activated STAT3 promotes proliferation primarily by stimulating
transcription of key cancer genes linked with proliferation of tumor
cells, such as cyclin D1, cyclin B and cdc2, which are involved in the reg-
ulation of cell cycle [127]. The active form of STAT3 was found to pro-
mote the G1/S phase transition of the cell cycle through the
expression of cyclin D1, which can associate with cdk4 or cdk6 and con-
trol progression from G1 to S phase in gastric [137] and colorectal [138]
cancer cells. STAT3 was found to be phosphorylated in 19% of bladder
cancer tissues as well as s veral bladder cancer cell lines. Targeting
the STAT3 signaling pathway in bladder cancer cells using an
adenovirus-mediated dominant-negative STAT3 prohibited cell growth
and induction of apoptosis i bladder cancer cell lines through down-
regulation of cell cycle-regulating gene cyclin D1 [139]. In human
head and neck squamous cell carcinoma, constitutive activation of
STAT3 was found to play a causative role in over-expression of cyclin
D1, and in clinical studies, STAT3 activation level provided a novel prog-
nostic factor [140]. Cucurbitacin I-mediated inhibition of STAT3-
induced cell-cycle arrest at the G2/M transition in cell lines derived
from laryngeal squamous cell carcinoma and glioblastomawas associat-
ed with the downregulation of cyclin B1 and cdc2 [138]. Constitutively
phosphorylated STAT3 has been found to induce over-expression of tar-
get genes such as cdc2, cyclin B1, m-ras, and E2F-1 in colon and breast
carcinomas. E2F-1 is a transcription factor that activates the synthesis
of mRNAs encoding proteins needed during the cell cycle. The products
of some E2F-1-regulated genes, such as cyclin D1 and cyclin E, cdc2 and
Fig. 2.Multifaceted role of STAT3 in tumor invasion and metastasis.
140 K.S. Siveen et al. / Biochimica et Biophysica Acta 1845 (2014) 136–154
Figure 19: STAT3 target genes. obtained from: Bishayee et al., 
Targeting the STAT3 signaling pathway in cancer: Role of synthetic and 
natural inhibitors, Biochimica et Biophysica Acta 1845,136–154p, 
(2014).  
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In summary, many studies have provided further evidence to the importance of 
STAT3 as a therapeutic target. Our current findings demonstrate that Manuka honey 
has the ability to inhibit the autocrine/paracrine feedback loop of IL-6/STAT3 
signaling pathway in human breast cancer cells leading to growth arrest and loss in 
viability. This cellular target is crucial since it plays critical roles in malignant 
progression, invasion, angiogenesis, survival, chemotherapy resistance and immune 
evasion. Inactivation of STAT3 leads to a loss in its transcriptional activity and, 
consequently, loss in the expression of many of the genes under STAT3 
transcriptional regulation. 
Finally, additional studies are needed to delineate exactly how Manuka honey 
achieves this effect. Possible mechanisms include the direct inhibition of the JAK2 
tyrosine kinase activity, prevention of ligand binding to IL-6 receptor or through 
inducing the degradation of the cytokine receptor. Additionally, further analysis is 
needed to investigate in depth the characteristics of the active compounds in Manuka 
honey and compare them directly with known purified phytochemicals.  
In conclusion, our findings identified IL-6/STAT3 signaling pathway as an early 
target of the anti-tumor activity of Manuka honey in human breast cancer cells. 
Given the demonstrated importance of this pathway in regulating the growth of 
different types of human tumors, Manuka honey may exert similar inhibitory effects 
on a range of cancers.     
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